drug_type
RELEVANT_DRUG
intervention_type
Therapeutic cancer vaccine (lentiviral vector gene therapy), intramuscular injection
drug_description
A lentiviral vector-based therapeutic cancer vaccine (gene therapy immunotherapy) encoding HPV16/18 E6/E7 antigens. Delivered by intramuscular injection, it transduces antigen-presenting cells to express E6/E7, leading to MHC I/II presentation and priming/expansion of HPV-specific CD8+ and CD4+ T-cell responses to kill HPV-positive tumor cells in cervical or oropharyngeal squamous cancers. The study evaluates 1–2 IM doses for safety, immunogenicity, and preliminary efficacy.
nci_thesaurus_concept_id
C211920
nci_thesaurus_preferred_term
HPV 16/18 E6/E7-encoding Lentiviral Vector-based Vaccine Lenti-HPV-07
nci_thesaurus_definition
A cancer vaccine consisting of a non-integrative lentiviral vector encoding the detoxified forms of the human papillomavirus (HPV) subtypes 16 and 18 viral oncoproteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration, HPV 16/18 E6/E7-encoding lentiviral vector-based vaccine Lenti-HPV-07 may elicit a specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HPV 16/18 E6 and E7 oncoproteins, resulting in tumor cell lysis. HPV infections and HPV oncoproteins play a key role in the development of cervical and other cancers, including oropharyngeal and anogenital cancers.
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
Non‑integrating lentiviral vector encoding detoxified HPV16/18 E6/E7 antigens is injected intramuscularly, transducing antigen‑presenting cells to express E6/E7. The antigens are processed and displayed on MHC I/II, priming and expanding HPV‑specific CD8+ cytotoxic and CD4+ helper T‑cell responses that recognize and kill HPV‑positive tumor cells.
drug_name
Lenti-HPV-07
nct_id_drug_ref
NCT06319963